Daniel Kerr Ii
Hematology & Oncology · Tampa, FLNPI 1821387135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,870 of the $192,502 with a category attached, or 68.5%. 60 manufacturers reported payments, led by Beigene USA, Inc. at 32.1% of the total. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $253.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$62K
- Genentech USA, Inc.$61K
- Beone Medicines USA, Inc.$24K
- E.r. Squibb & Sons, L.L.C.$10K
- Pfizer$7K
- AbbVie$5K
- plus $23K from 54 others
Across 52 payments — averaging $9163.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$362K
- Sanofi US Services Inc.$43K
- Bristol Myers Squibb$14K
- Eli Lilly$13K
- EMD Serono, Inc.$13K
- Genentech, Inc.$12K
- plus $21K from 3 others
What the payments were for
- Consulting fees$28,61215%
- Speaking & faculty fees$131,87069%
- Travel & lodging$11,1276%
- Food & beverage$20,40211%
- Education$4910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$192,502 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 87 | $971,004 |
| RevlimidLenalidomide | 41 | $667,484 |
| ScemblixAsciminib Hydrochloride | 16 | $328,479 |
| ImbruvicaIbrutinib | 19 | $328,187 |
| IclusigPonatinib Hcl | 14 | $268,507 |
| JakafiRuxolitinib Phosphate | 15 | $258,053 |
| IbrancePalbociclib | 14 | $214,085 |
| VenclextaVenetoclax | 68 | $205,162 |
| XtandiEnzalutamide | 17 | $111,760 |
| EliquisApixaban | 40 | $36,959 |
| Tranexamic Acid | 11 | $4,796 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $2,873 |
| Acyclovir | 100 | $1,988 |
| Oxycodone Hcl | 56 | $1,604 |
| Gabapentin | 21 | $1,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $61,845 | $971,00487 claims |
| Bristol Myers SquibbRevlimid | $1,149 | $667,48441 claims |
| NovartisScemblix | $906 | $328,47916 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $300 | $328,18719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $103 | $268,50714 claims |
| Incyte CorporationJakafi | $2,156 | $258,05315 claims |
| PfizerIbrance, Eliquis | $7,158 | $251,04454 claims |
| AbbVieVenclexta | $5,030 | $205,16268 claims |
| Astellas Pharma US IncXtandi | $452 | $111,76017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
- Melanie SheenTampa$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.